pmc logo image
Logo of annrheumdAnnals of the Rheumatic DiseasesCurrent TOCInstructions for authors
Journal List > Ann Rheum Dis > v.64(Suppl 4); Nov 2005

Formats:
Ann Rheum Dis. 2005 November; 64(Suppl 4): iv2–iv14.
doi: 10.1136/ard.2005.044941.
PMCID: PMC1766920
Copyright notice
Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005
D Furst, F Breedveld, J Kalden, J Smolen, G Burmester, J Bijlsma, M Dougados, P Emery, E Keystone, L Klareskog, and P Mease
Small right arrow pointing to: This article has been corrected. See Ann Rheum Dis. 2006 January; 65(1): 140.
 
Small right arrow pointing to: This article has been cited by other articles in PMC.
Full Text
The Full Text of this article is available as a PDF (161K).
Supplementary Material
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JWJ, Dougados M, Emery P, Keystone EC, Klareskog L, Mease PJ. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis. 2004 Nov;63 Suppl 2:ii2–ii12. [PubMed]
  • Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ. 1999 Feb 27;318(7183):593–596. [PubMed]
  • Wolfe F, Pincus T, O'Dell J. Evaluation and documentation of rheumatoid arthritis disease status in the clinic: which variables best predict change in therapy. J Rheumatol. 2001 Jul;28(7):1712–1717. [PubMed]
  • Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, van Riel PL, Tugwell P. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003 Feb;42(2):244–257. [PubMed]
  • Gladman Dafna D, Helliwell Philip, Mease Philip J, Nash Peter, Ritchlin Christopher, Taylor William. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum. 2004 Jan;50(1):24–35. [PubMed]
  • Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003 Jun;48(6):1667–1675. [PubMed]
  • Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sörensen H, Zeidler H, Thriene W, Sieper J. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002 Apr 6;359(9313):1187–1193. [PubMed]
  • Davis John C, Jr, Van Der Heijde Désirée, Braun Jurgen, Dougados Maxime, Cush John, Clegg Daniel O, Kivitz Alan, Fleischmann Roy, Inman Robert, Tsuji Wayne. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003 Nov;48(11):3230–3236. [PubMed]
  • Gorman Jennifer D, Sack Kenneth E, Davis John C., Jr Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002 May 2;346(18):1349–1356. [PubMed]
  • Van Den Bosch Filip, Kruithof Elli, Baeten Dominique, Herssens Annemie, de Keyser Filip, Mielants Herman, Veys Eric M. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum. 2002 Mar;46(3):755–765. [PubMed]
  • Bang Lynne M, Keating Gillian M. Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs. 2004;18(2):121–139. [PubMed]
  • Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000 Nov 30;343(22):1586–1593. [PubMed]
  • Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR, St Clair EW, Weisman M, Smolen J, Lipsky PE, Maini RN. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis. 2004 Feb;63(2):149–155. [PubMed]
  • Culy Christine R, Keating Gillian M. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs. 2002;62(17):2493–2537. [PubMed]
  • Cummins Carole, Connock M, Fry-Smith A, Burls A. A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept. Health Technol Assess. 2002;6(17):1–43. [PubMed]
  • Curran Shane A, FitzGerald Oliver M, Costello Patrick J, Selby Jeanette M, Kane David J, Bresnihan Barry, Winchester Robert. Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing autoantigens. J Immunol. 2004 Feb 1;172(3):1935–1944. [PubMed]
  • Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993 Dec;36(12):1681–1690. [PubMed]
  • Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet. 1994 Oct 22;344(8930):1125–1127. [PubMed]
  • Furst Daniel E, Schiff Michael H, Fleischmann Roy M, Strand Vibeke, Birbara Charles A, Compagnone Daniele, Fischkoff Steven A, Chartash Elliot K. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003 Dec;30(12):2563–2571. [PubMed]
  • Garrison L, McDonnell ND. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis. 1999 Nov;58 Suppl 1:I65–I69. [PubMed]
  • Genovese Mark C, Bathon Joan M, Martin Richard W, Fleischmann Roy M, Tesser John R, Schiff Michael H, Keystone Edward C, Wasko Mary Chester, Moreland Larry W, Weaver Arthur L, Markenson Joseph, Cannon Grant W, Spencer-Green George, Finck Barbara K. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002 Jun;46(6):1443–1450. [PubMed]
  • Harriman G, Harper LK, Schaible TF. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment. Ann Rheum Dis. 1999 Nov;58 Suppl 1:I61–I64. [PubMed]
  • Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs. 1999 Jun;57(6):945–966. [PubMed]
  • Jones RE, Moreland LW. Tumor necrosis factor inhibitors for rheumatoid arthritis. Bull Rheum Dis. 1999;48(3):1–4. [PubMed]
  • Kavanaugh AF. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am. 1998 Aug;24(3):593–614. [PubMed]
  • Klareskog Lars, van der Heijde Désirée, de Jager Julien P, Gough Andrew, Kalden Joachim, Malaise Michel, Martín Mola Emilio, Pavelka Karel, Sany Jacques, Settas Lucas, Wajdula Joseph, Pedersen Ronald, Fatenejad Saeed, Sanda Marie. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004 Feb 28;363(9410):675–681. [PubMed]
  • Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000 Nov 30;343(22):1594–1602. [PubMed]
  • Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000 Mar 16;342(11):763–769. [PubMed]
  • Lovell Daniel J, Giannini Edward H, Reiff Andreas, Jones Olcay Y, Schneider Rayfel, Olson Judyann C, Stein Leonard D, Gedalia Abraham, Ilowite Norman T, Wallace Carol A, Lange Mary, Finck Barbara K, Burge Daniel J. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 2003 Jan;48(1):218–226. [PubMed]
  • Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs. 2000 Jun;59(6):1341–1359. [PubMed]
  • Moreland LW, Margolies G, Heck LW, Jr, Saway A, Blosch C, Hanna R, Koopman WJ. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol. 1996 Nov;23(11):1849–1855. [PubMed]
  • Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999 Mar 16;130(6):478–486. [PubMed]
  • van de Putte LBA, Atkins C, Malaise M, Sany J, Russell AS, van Riel PLCM, Settas L, Bijlsma JW, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff S, Kupper H. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004 May;63(5):508–516. [PubMed]
  • Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998 Sep;41(9):1552–1563. [PubMed]
  • Scheinfeld Noah. Adalimumab (HUMIRA): a review. J Drugs Dermatol. 2003 Aug;2(4):375–377. [PubMed]
  • Antoni Christian, Dechant Claudia, Hanns-Martin Lorenz PD, Wendler Joerg, Ogilvie Alexandra, Lueftl Mathias, Kalden-Nemeth Dolores, Kalden Joachim R, Manger Bernhard. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum. 2002 Oct 15;47(5):506–512. [PubMed]
  • Mease PJ. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis. Skin Therapy Lett. 2003 Jan;8(1):1–4. [PubMed]
  • Cauza Edmund, Spak Marita, Cauza Karla, Hanusch-Enserer Ursula, Dunky Attila, Wagner Ernst. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Rheumatol Int. 2002 Nov;22(6):227–232. [PubMed]
  • Feletar M, Brockbank JE, Schentag CT, Lapp V, Gladman DD. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis. 2004 Feb;63(2):156–161. [PubMed]
  • Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000 Jul 29;356(9227):385–390. [PubMed]
  • Mease Philip J, Kivitz Alan J, Burch Francis X, Siegel Evan L, Cohen Stanley B, Ory Peter, Salonen David, Rubenstein Joel, Sharp John T, Tsuji Wayne. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004 Jul;50(7):2264–2272. [PubMed]
  • Ogilvie AL, Antoni C, Dechant C, Manger B, Kalden JR, Schuler G, Lüftl M. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol. 2001 Mar;144(3):587–589. [PubMed]
  • Salvarani Carlo, Cantini Fabrizio, Olivieri Ignazio, Macchioni Pierluigi, Padula Angela, Niccoli Laura, Catanoso Maria Grazia, Scocco Giovanni Lo, Boiardi Luigi. Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum. 2003 Aug 15;49(4):541–545. [PubMed]
  • Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005 Aug;64(8):1150–1157. [PubMed]
  • Antoni Christian E, Kavanaugh Arthur, Kirkham Bruce, Tutuncu Zuhre, Burmester Gerd R, Schneider Udo, Furst Daniel E, Molitor Jerry, Keystone Edward, Gladman Dafna, Manger Bernhard, Wassenberg Siegfried, Weier Ralf, Wallace Daniel J, Weisman Michael H, Kalden Joachim R, Smolen Josef. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005 Apr;52(4):1227–1236. [PubMed]
  • Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, Budiman-Mak E, Blackburn WD, Vasey FB, Mahowald ML, Cush JJ, Schumacher HR, Jr, Silverman SL, Alepa FP, Luggen ME, Cohen MR, Makkena R, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Ward JR, Henderson WG. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996 Dec;39(12):2013–2020. [PubMed]
  • Dougados M, vam der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, Zeidler H, Kvien TK, Olivieri I, Dijkmans B, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. 1995 May;38(5):618–627. [PubMed]
  • Goupille P, Valat JP. Sulfasalazine: a definitively efficient treatment for psoriatic arthritis. J Rheumatol. 1996 Apr;23(4):791–792. [PubMed]
  • Spadaro A, Riccieri V, Sili-Scavalli A, Sensi F, Taccari E, Zoppini A. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol. 1995 Sep–Oct;13(5):589–593. [PubMed]
  • Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ, Cathcart ES, Samuelson CO, Jr, Solsky MA, Kaplan SB, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 1984 Apr;27(4):376–381. [PubMed]
  • Tutrone William D, Saini Rita, Weinberg Jeffery M. Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept. IDrugs. 2004 Jan;7(1):45–49. [PubMed]
  • Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001 Jun 9;357(9271):1842–1847. [PubMed]
  • Scheinfeld N. Adalimumab (Humira): a brief review for dermatologists. J Dermatolog Treat. 2004 Dec;15(6):348–352. [PubMed]
  • Gottlieb Alice B, Chaudhari Umesh, Mulcahy Lisa D, Li Shu, Dooley Lisa T, Baker Daniel G. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol. 2003 Jun;48(6):829–835. [PubMed]
  • Leonardi Craig L, Powers Jerold L, Matheson Robert T, Goffe Bernard S, Zitnik Ralph, Wang Andrea, Gottlieb Alice B. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003 Nov 20;349(21):2014–2022. [PubMed]
  • Braun J, Pham T, Sieper J, Davis J, van der Linden Sj, Dougados M, van der Heijde D. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2003 Sep;62(9):817–824. [PubMed]
  • van der Heijde Désirée, Dijkmans Ben, Geusens Piet, Sieper Joachim, DeWoody Kimberly, Williamson Paul, Braun Jürgen. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005 Feb;52(2):582–591. [PubMed]
  • Baraliakos Xenofon, Listing Joachim, Brandt Jan, Zink Angela, Alten Rieke, Burmester Gerd, Gromnica-Ihle Erika, Kellner Herbert, Schneider Matthias, Sörensen Helmut, Zeidler Henning, Rudwaleit Martin, Sieper Joachim, Braun Juergen. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther. 2005;7(3):R439–R444. [PubMed]
  • Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis. 2005 Feb;64(2):229–234. [PubMed]
  • Scheinfeld Noah. Adalimumab: a review of side effects. Expert Opin Drug Saf. 2005 Jul;4(4):637–641. [PubMed]
  • Emery Paul. Review of health economics modelling in rheumatoid arthritis. Pharmacoeconomics. 2004;22(2 Suppl 1):55–69. [PubMed]
  • Kavanaugh Arthur, Han Chenglong, Bala Mohan. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol. 2004 May;31(5):849–855. [PubMed]
  • Yelin Edward H, Trupin Laura S, Katz Patricia P. Impact of managed care on the use of biologic agents for rheumatoid arthritis. Arthritis Rheum. 2005 Jun 15;53(3):423–430. [PubMed]
  • Wong JB. Cost-effectiveness of anti-tumor necrosis factor agents. Clin Exp Rheumatol. 2004 Sep–Oct;22(5 Suppl 35):S65–S70. [PubMed]
  • Merkesdal Sonja, Ruof Jörg, Mittendorf Thomas, Zeidler Henning. Cost-effectiveness of TNF-alpha-blocking agents in the treatment of rheumatoid arthritis. Expert Opin Pharmacother. 2004 Sep;5(9):1881–1886. [PubMed]
  • Bansback Nick J, Regier Dean A, Ara Roberta, Brennan Alan, Shojania Kamran, Esdaile John M, Anis Aslam H, Marra Carlo A. An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists. Drugs. 2005;65(4):473–496. [PubMed]
  • Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis. 2005 Jul;64(7):995–1002. [PubMed]
  • Kaplan Robert M, Groessl Erik J, Sengupta Nishan, Sieber William J, Ganiats Theodore G. Comparison of measured utility scores and imputed scores from the SF-36 in patients with rheumatoid arthritis. Med Care. 2005 Jan;43(1):79–87. [PubMed]
  • Zein Nizar N. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005 Mar;42(3):315–322. [PubMed]
  • Melikoglu Melike, Fresko Izzet, Mat Cem, Ozyazgan Yilmaz, Gogus Feride, Yurdakul Sebahattin, Hamuryudan Vedat, Yazici Hasan. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol. 2005 Jan;32(1):98–105. [PubMed]
  • Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjögren's syndrome: a pilot study. Arthritis Rheum. 2001 Oct;44(10):2371–2375. [PubMed]
  • Mariette Xavier, Ravaud Philippe, Steinfeld Serge, Baron Gabriel, Goetz Joelle, Hachulla Eric, Combe Bernard, Puéchal Xavier, Pennec Yvon, Sauvezie Bernard, Perdriger Aleth, Hayem Gilles, Janin Anne, Sibilia Jean. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum. 2004 Apr;50(4):1270–1276. [PubMed]
  • Sankar Vidya, Brennan Michael T, Kok Marc R, Leakan Rose Anne, Smith Janine A, Manny Joan, Baum Bruce J, Pillemer Stanley R. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004 Jul;50(7):2240–2245. [PubMed]
  • Kraetsch HG, Antoni C, Kalden JR, Manger B. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. Ann Rheum Dis. 2001 Nov;60 Suppl 3:iii55–iii57. [PubMed]
  • Husni M Elaine, Maier Agnes L, Mease Philip J, Overman Steven S, Fraser Patricia, Gravallese Ellen M, Weinblatt Michael E. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum. 2002 May;46(5):1171–1176. [PubMed]
  • Elkayam Ori, Hawkins Philip N, Lachmann Helen, Yaron Michael, Caspi Dan. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum. 2002 Oct;46(10):2571–2573. [PubMed]
  • Gottenberg Jacques-Eric, Merle-Vincent Florence, Bentaberry Fabrice, Allanore Yannick, Berenbaum Francis, Fautrel Bruno, Combe Bernard, Durbach Antoine, Sibilia Jean, Dougados Maxime, Mariette Xavier. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum. 2003 Jul;48(7):2019–2024. [PubMed]
  • Gulli Salvatore, Arrigo Carlo, Bocchino Loredana, Morgante Lucia, Sangari Donatella, Castagna Irene, Bagnato Gian Filippo. Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report. BMC Musculoskelet Disord. 2003 Aug 28;4:19–19. [PubMed]
  • Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology. 2001 Mar;120(4):995–999. [PubMed]
  • Licata G, Pinto A, Tuttolomondo A, Banco A, Ciccia F, Ferrante A, Triolo G. Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome. Ann Rheum Dis. 2003 Mar;62(3):280–281. [PubMed]
  • Rozenbaum M, Rosner I, Portnoy E. Remission of Behçet's syndrome with TNFalpha blocking treatment. Ann Rheum Dis. 2002 Mar;61(3):283–284. [PubMed]
  • Saulsbury Frank T, Mann James A. Treatment with infliximab for a child with Behçet's disease. Arthritis Rheum. 2003 Aug 15;49(4):599–600. [PubMed]
  • Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet. 2001 Jul 28;358(9278):295–296. [PubMed]
  • Sfikakis PP. Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii51–ii53. [PubMed]
  • Naveau Sylvie, Chollet-Martin Sylvie, Dharancy Sébastien, Mathurin Philippe, Jouet Pauline, Piquet Marie-Astrid, Davion Thierry, Oberti Frédéric, Broët Philippe, Emilie Dominique. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology. 2004 May;39(5):1390–1397. [PubMed]
  • Wendling D, Auge B, Bettinger D, Lohse A, Le Huede G, Bresson-Hadni S, Toussirot E, Miguet J-P, Herbein G, Di Martino V. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis. 2005 May;64(5):788–789. [PubMed]
  • Spahr Laurent, Rubbia-Brandt Laura, Frossard Jean-Loius, Giostra Emile, Rougemont Anne-Laure, Pugin Jérôme, Fischer Maria, Egger Hanspeter, Hadengue Antoine. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol. 2002 Oct;37(4):448–455. [PubMed]
  • Tsimberidou Apostolia-Maria, Giles Francis J, Duvic Madeleine, Kurzrock Razelle. Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. J Am Acad Dermatol. 2004 Aug;51(2):200–204. [PubMed]
  • Sprott H, Glatzel M, Michel BA. Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1. Rheumatology (Oxford). 2004 Apr;43(4):524–526. [PubMed]
  • Hull Keith M, Drewe Elizabeth, Aksentijevich Ivona, Singh Harjot K, Wong Kondi, McDermott Elizabeth M, Dean Jane, Powell Richard J, Kastner Daniel L. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore). 2002 Sep;81(5):349–368. [PubMed]
  • Takada Kazuki, Aksentijevich Ivona, Mahadevan Vijayabhanu, Dean Jane A, Kelley Richard I, Kastner Daniel L. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum. 2003 Sep;48(9):2645–2651. [PubMed]
  • Andonopoulos AP, Meimaris N, Daoussis D, Bounas A, Giannopoulos G. Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis. 2003 Nov;62(11):1116. [PubMed]
  • Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum. 2001 Dec;44(12):2933–2935. [PubMed]
  • Tan AL, Holdsworth J, Pease C, Emery P, McGonagle D. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis. 2003 Apr;62(4):373–374. [PubMed]
  • Parke Frank A, Reveille John D. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum. 2004 Oct 15;51(5):800–804. [PubMed]
  • Magliocco Melissa Amy, Gottlieb Alice Bendix. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol. 2004 Oct;51(4):580–584. [PubMed]
  • Cacoub Patrice, Lidove Olivier, Maisonobe Thierry, Duhaut Pierre, Thibault Vincent, Ghillani Pascale, Myers Robert P, Leger Jean Marc, Servan Jérôme, Piette Jean-Charles. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum. 2002 Dec;46(12):3317–3326. [PubMed]
  • McMinn JR, Jr, Cohen Stephen, Moore Joseph, Lilly Scott, Parkhurst Joan, Tarantino Michael D, Terrell Deirdra R, George James N. Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept. Am J Hematol. 2003 Jun;73(2):135–140. [PubMed]
  • Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis. 2003 Nov;62(11):1078–1082. [PubMed]
  • Burns Jane C, Mason Wilbert H, Hauger Sarmistha B, Janai Hillel, Bastian John F, Wohrley Julie D, Balfour Ian, Shen Cynthia A, Michel Edward D, Shulman Stanford T, Melish Marian E. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005 May;146(5):662–667. [PubMed]
  • Weiss Jennifer E, Eberhard B Anne, Chowdhury Devyani, Gottlieb Beth S. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol. 2004 Apr;31(4):808–810. [PubMed]
  • Birnbaum AJ, Gentile P. Treatment of myelodysplasia in a patient with active rheumatoid arthritis. Ann Intern Med. 2000 Nov 7;133(9):753–754. [PubMed]
  • Kroot E-JA, Kraan MC, Smeets TJM, Maas M, Tak PP, Wouters JMGW. Tumour necrosis factor alpha blockade in treatment resistant pigmented villonodular synovitis. Ann Rheum Dis. 2005 Mar;64(3):497–499. [PubMed]
  • Wagner Annette D, Andresen Jan, Jendro Michael C, Hülsemann Jan L, Zeidler Henning. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum. 2002 Jul;46(7):1965–1968. [PubMed]
  • Tutuncu Z, Morgan GJ, Jr, Kavanaugh A. Anti-TNF therapy for other inflammatory conditions. Clin Exp Rheumatol. 2002 Nov–Dec;20(6 Suppl 28):S146–S151. [PubMed]
  • Khanna Dinesh, Liebling Michael R, Louie James S. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol. 2003 Aug;30(8):1864–1867. [PubMed]
  • Baughman Robert P, Iannuzzi Michael. Tumour necrosis factor in sarcoidosis and its potential for targeted therapy. BioDrugs. 2003;17(6):425–431. [PubMed]
  • Utz James P, Limper Andrew H, Kalra Sanjay, Specks Ulrich, Scott John P, Vuk-Pavlovic Zvezdana, Schroeder Darrell R. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003 Jul;124(1):177–185. [PubMed]
  • Korhonen Timo, Karppinen Jaro, Malmivaara Antti, Autio Reijo, Niinimäki Jaakko, Paimela Leena, Kyllönen Eero, Lindgren Karl-August, Tervonen Osmo, Seitsalo Seppo, Hurri Heikki. Efficacy of infliximab for disc herniation-induced sciatica: one-year follow-up. Spine (Phila Pa 1976). 2004 Oct 1;29(19):2115–2119. [PubMed]
  • Atcheson Steven G, Dymeck Terri. Rapid resolution of chronic sciatica with intravenous infliximab after failed epidural steroid injections. Spine (Phila Pa 1976). 2004 Jun 15;29(12):E248–E250. [PubMed]
  • Genevay S, Stingelin S, Gabay C. Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study. Ann Rheum Dis. 2004 Sep;63(9):1120–1123. [PubMed]
  • Aringer Martin, Graninger Winfried B, Steiner Günter, Smolen Josef S. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 2004 Oct;50(10):3161–3169. [PubMed]
  • Principi M, Di Leo A, Ingrosso M, Pisani A, Marangi S, Amoruso A, Panella C, Francavilla A, Ierardi Enzo. Lupus nephritis improvement after anti-tumor necrosis factor alpha monoclonal antibody (infliximab) treatment for Crohn's disease: a case report. Immunopharmacol Immunotoxicol. 2004 May;26(2):243–248. [PubMed]
  • Hoffman Gary S, Merkel Peter A, Brasington Richard D, Lenschow Deborah J, Liang Patrick. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum. 2004 Jul;50(7):2296–2304. [PubMed]
  • Joseph Annie, Raj Dev, Dua Harminder S, Powell Pauline T, Lanyon Peter C, Powell Richard J. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology. 2003 Jul;110(7):1449–1453. [PubMed]
  • Booth Anthony, Harper Lorraine, Hammad Tariq, Bacon Paul, Griffith Megan, Levy Jeremy, Savage Caroline, Pusey Charles, Jayne David. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 2004 Mar;15(3):717–721. [PubMed]
  • Brocq O, Plubel Y, Breuil V, Grisot C, Flory P, Mousnier A, Euller-Ziegler L. Switch étanercept--infliximab dans la polyarthrite rhumatoïde. 14 patients sur 132 traités par anti-TNFalpha. Presse Med. 2002 Nov 23;31(39 Pt 1):1836–1839. [PubMed]
  • Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis. 2003 Nov;62 Suppl 2:ii13–ii16. [PubMed]
  • van Vollenhoven RF, Brannemark S, Klareskog L. Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann Rheum Dis. 2004 Apr;63(4):426–430. [PubMed]
  • Buch Maya H, Seto Yohei, Bingham Sarah J, Bejarano Victoria, Bryer Domini, White Jo, Emery Paul. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum. 2005 Jan;52(1):42–48. [PubMed]
  • Heiberg Marte S, Nordvåg Bjørn-Yngvar, Mikkelsen Knut, Rødevand Erik, Kaufmann Cecilie, Mowinckel Petter, Kvien Tore K. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study. Arthritis Rheum. 2005 Aug;52(8):2506–2512. [PubMed]
  • Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, Breedveld FC, Furst DE, Lipsky PE. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005 Apr;52(4):1020–1030. [PubMed]
  • Quinn Mark A, Conaghan Philip G, O'Connor Philip J, Karim Zunaid, Greenstein Adam, Brown Andrew, Brown Clare, Fraser Alexander, Jarret Stephen, Emery Paul. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005 Jan;52(1):27–35. [PubMed]
  • Hyrich KL, Silman AJ, Watson KD, Symmons DPM. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis. 2004 Dec;63(12):1538–1543. [PubMed]
  • Mohan Aparna K, Coté Timothy R, Block Joel A, Manadan Augustine M, Siegel Jeffrey N, Braun M Miles. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis. 2004 Aug 1;39(3):295–299. [PubMed]
  • Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004 May 1;38(9):1261–1265. [PubMed]
  • Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther. 1999 Sep;13 Suppl 4:16–38. [PubMed]
  • Wallis Robert S, Broder Michael, Wong John, Beenhouwer David. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis. 2004 Oct 15;39(8):1254–1255. [PubMed]
  • Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001 Oct 11;345(15):1098–1104. [PubMed]
  • Khanna Dinesh, McMahon Maureen, Furst Daniel E. Safety of tumour necrosis factor-alpha antagonists. Drug Saf. 2004;27(5):307–324. [PubMed]
  • Lee Jong-Hoon, Slifman Nancy R, Gershon Sharon K, Edwards Evelyne T, Schwieterman William D, Siegel Jeffrey N, Wise Robert P, Brown S Lori, Udall John N, Jr, Braun M Miles. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002 Oct;46(10):2565–2570. [PubMed]
  • Manadan AM, Block JA, Sequeira W. Mycobacteria tuberculosis peritonitis associated with etanercept therapy. Clin Exp Rheumatol. 2003 Jul–Aug;21(4):526. [PubMed]
  • Doran Michele F, Crowson Cynthia S, Pond Gregory R, O'Fallon W Michael, Gabriel Sherine E. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002 Sep;46(9):2294–2300. [PubMed]
  • Doran Michele F, Crowson Cynthia S, Pond Gregory R, O'Fallon W Michael, Gabriel Sherine E. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002 Sep;46(9):2287–2293. [PubMed]
  • Slifman Nancy R, Gershon Sharon K, Lee Jong-Hoon, Edwards Evelyne T, Braun M Miles. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003 Feb;48(2):319–324. [PubMed]
  • Elkayam Ori, Caspi Dan, Reitblatt Tatiana, Charboneau Darlene, Rubins Jeffrey B. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum. 2004 Feb;33(4):283–288. [PubMed]
  • Mease Phillip J, Ritchlin Christopher T, Martin Richard W, Gottlieb Alice B, Baumgartner Scott W, Burge Daniel J, Whitmore James B. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol. 2004 Jul;31(7):1356–1361. [PubMed]
  • Baecklund E, Ekbom A, Sparén P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ. 1998 Jul 18;317(7152):180–181. [PubMed]
  • Geborek P, Bladström A, Turesson C, Gulfe A, Petersson IF, Saxne T, Olsson H, Jacobsson LTH. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005 May;64(5):699–703. [PubMed]
  • Prior P, Symmons DP, Hawkins CF, Scott DL, Brown R. Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis. 1984 Apr;43(2):128–131. [PubMed]
  • Lohmander LS, McKeith D, Svensson O, Malmenäs M, Bolin L, Kalla A, Genti G, Szechinski J, Ramos-Remus C. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis. 2005 Mar;64(3):449–456. [PubMed]
  • Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum. 2001 May;44(5):1149–1154. [PubMed]
  • Khanna Dinesh, McMahon Maureen, Furst Daniel E. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum. 2004 Apr;50(4):1040–1050. [PubMed]
  • Khanna M, Shirodkar MA, Gottlieb AB. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatolog Treat. 2003 Dec;14(4):229–232. [PubMed]
  • Oniankitan Owonayo, Duvoux Christophe, Challine Dominique, Mallat Arianne, Chevalier Xavier, Pawlotsky Jean-Michel, Claudepierre Pascal. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol. 2004 Jan;31(1):107–109. [PubMed]
  • Esteve M, Saro C, González-Huix F, Suarez F, Forné M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut. 2004 Sep;53(9):1363–1365. [PubMed]
  • Schiemann U, Kellner H. Gastrointestinale Nebenwirkungen der Therapie rheumatischer Erkrankungen. Z Gastroenterol. 2002 Nov;40(11):937–943. [PubMed]
  • De Rycke Leen, Kruithof Elli, Van Damme Nancy, Hoffman Ilse E A, Van den Bossche Nancy, Van den Bosch Filip, Veys Eric M, De Keyser Filip. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum. 2003 Apr;48(4):1015–1023. [PubMed]
  • Eriksson C, Engstrand S, Sundqvist K-G, Rantapää-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis. 2005 Mar;64(3):403–407. [PubMed]
  • Allanore Y, Sellam J, Batteux F, Job Deslandre C, Weill B, Kahan A. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clin Exp Rheumatol. 2004 Nov–Dec;22(6):756–758. [PubMed]
  • Hanauer Stephen B, Wagner Carrie L, Bala Mohan, Mayer Lloyd, Travers Suzanne, Diamond Robert H, Olson Allan, Bao Warren, Rutgeerts Paul. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004 Jul;2(7):542–553. [PubMed]
  • Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum. 1996 Jul;39(7):1092–1101. [PubMed]
  • Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, Hanrahan PS, Kraishi MM, Patel A, Sun G, Bear MB. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis. 2004 Sep;63(9):1062–1068. [PubMed]
  • Cohen Stanley, Hurd Eric, Cush John, Schiff Michael, Weinblatt Michael E, Moreland Larry W, Kremer Joel, Bear Moraye B, Rich William J, McCabe Dorothy. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Mar;46(3):614–624. [PubMed]
  • Fleischmann Roy M, Schechtman Joy, Bennett Ralph, Handel Malcolm L, Burmester Gerd-Rudiger, Tesser John, Modafferi Dennis, Poulakos Jennifer, Sun Gordon. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 2003 Apr;48(4):927–934. [PubMed]
  • Verbsky James W, White Andrew J. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2004 Oct;31(10):2071–2075. [PubMed]
  • Müller K, Zak M, Nielsen S, Pedersen FK, de Nully P, Bendtzen K. Interleukin-1 receptor antagonist in neonates, children and adults, and in patients with pauci- and polyarticular onset juvenile chronic arthritis. Clin Exp Rheumatol. 1997 Jul–Aug;15(4):439–444. [PubMed]
  • Vasques Godinho FM, Parreira Santos MJ, Canas da Silva J. Refractory adult onset Still's disease successfully treated with anakinra. Ann Rheum Dis. 2005 Apr;64(4):647–648. [PubMed]
  • Lovell Daniel J, Bowyer Suzanne L, Solinger Alan M. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum. 2005 Apr;52(4):1283–1286. [PubMed]
  • Hawkins Philip N, Lachmann Helen J, Aganna Ebun, McDermott Michael F. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 2004 Feb;50(2):607–612. [PubMed]
  • Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis. 2005 Apr;64(4):630–633. [PubMed]
  • Tan AL, Marzo-Ortega H, O'Connor P, Fraser A, Emery P, McGonagle D. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis. 2004 Sep;63(9):1041–1045. [PubMed]
  • Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis. 2005 Feb;64(2):296–298. [PubMed]
  • Genant HK. Interleukin-1 receptor antagonist treatment of rheumatoid arthritis patients: radiologic progression and correlation of Genant/Sharp and Larsen scoring methods. Semin Arthritis Rheum. 2001 Apr;30(5 Suppl 2):26–32. [PubMed]
  • Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, McCabe D. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 2000 May;43(5):1001–1009. [PubMed]
  • Bresnihan Barry, Newmark Richard, Robbins Sean, Genant Harry K. Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. J Rheumatol. 2004 Jun;31(6):1103–1111. [PubMed]
  • Tesser John, Fleischmann Roy, Dore Robin, Bennett Ralph, Solinger Alan, Joh Tenshang, Modafferi Dennis, Schechtman Joy. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis. J Rheumatol. 2004 Apr;31(4):649–654. [PubMed]
  • Genovese Mark C, Cohen Stanley, Moreland Larry, Lium Deborah, Robbins Sean, Newmark Richard, Bekker Pirow. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 2004 May;50(5):1412–1419. [PubMed]
Articles from Annals of the Rheumatic Diseases are provided here courtesy of
BMJ Group

PubMed articles by these authors